“The future belongs to companies that can bridge disciplines, reduce friction, and keep people at the center of innovation.”
That perspective perfectly captures the insights shared by Julie Moon, MBA, Chief Strategy Officer at Global Regulatory Writing & Consulting (Global RWC), during this episode of the Life Sciences – In Focus podcast.
From her beginnings on a family farm to leading strategic growth initiatives across biotech and med tech, Julie brings a uniquely grounded perspective to the evolving world of regulatory strategy, advanced therapies, and AI-enabled innovation.
From Farm Life to Global Regulatory Leadership
Growing up on a family farm, Julie learned the value of hard work early, helping cultivate organic produce and gaining firsthand exposure to biology and science through nature itself. That upbringing shaped more than just her work ethic. It instilled a deep sense of purpose.
“We didn’t grow up with much ourselves,” Julie shared, “but my parents were always helping others whenever they could.”
That mindset continues to guide her career today, particularly in helping bring meaningful therapies and medical technologies to patients who need them most.
Over the years, Julie has built extensive experience across biotech and med tech, spanning quality systems, regulatory affairs, manufacturing, operations, product development, and business leadership. She has led global teams, built organizations from the ground up, and even launched and operated her own business.
But throughout every role, one theme has remained constant: purpose-driven leadership.
What Makes Global RWC Different?
As Chief Strategy Officer at Global Regulatory Writing & Consulting, Julie helps lead a company focused on supporting biotech and med tech organizations across the entire product lifecycle – from early-stage development through post-commercialization.
“Our job is to help get products approved – quickly, correctly, and strategically,” Julie explained.
Global RWC operates through two highly specialized divisions: biotech and medtech. This structure allows the company to support increasingly complex products while maintaining deep technical expertise in each domain.
Julie emphasized the importance of reducing friction for clients, especially emerging companies navigating investor pressure, regulatory demands, and accelerated development timelines.
Many of Global’s clients are ambitious organizations. For these companies, having a responsive and collaborative regulatory partner can make a significant difference. Rather than functioning as a traditional service provider, Global positions itself as a strategic extension of the client team.
The Power of Real-World Industry Experience
One of the company’s major differentiators is the practical industry experience of its consultants. Many members of the Global RWC team have worked directly in manufacturing environments, development labs, quality systems, analytical development, and technology transfer.
That operational experience shapes the way they approach regulatory strategy.
“It’s not just about writing documents,” Julie explained. “It’s understanding what’s realistic operationally and anticipating what health authorities are likely to focus on.” This hands-on perspective allows the team to develop solutions that are not only compliant but also executable in real-world settings.
GXT: Building Smarter Tools for Regulatory Professionals
Alongside Global RWC, Julie also discussed Global Exponential Technologies (GXT), the company’s sister organization, which focuses on developing next-generation software solutions for regulatory and technical professionals.
GXT’s mission is not to replace experts, but to empower them.
The company is building tools that improve efficiency, organization, traceability, and collaboration within regulatory workflows.
Julie highlighted several areas where AI-assisted technologies can provide value:
- Accelerating document structure and drafting
- Creating traceability matrices
- Organizing large data sets
- Improving information retrieval
- Streamlining collaboration across teams
The goal is to free highly skilled professionals from repetitive manual tasks so they can focus on strategic decision-making and scientific interpretation.
AI in Regulatory Writing: Enhancement, Not Replacement
As AI continues to dominate conversations in life sciences, Julie offered a balanced, pragmatic perspective on its role in regulatory writing.
The short answer to whether Global uses AI to author regulatory submissions independently? “No.”
While Julie sees tremendous potential for AI-enabled efficiencies, she emphasized that human expertise remains essential in highly regulated industries. “Regulatory writing isn’t just assembling words on a page,” she explained. “It’s understanding the science, the strategy, the risks, and the operational realities.”
She also highlighted the importance of protecting sensitive client data and intellectual property, noting that organizations cannot simply upload confidential development reports into public AI tools.
For Julie, the future is not AI versus humans – it’s AI plus experienced human judgment.
“The ideal model is where technology helps experts work faster, but people remain fully accountable and in control.”
Advanced Therapies and the Future of Product Development
Looking ahead to 2026 and beyond, Julie sees enormous momentum in advanced therapies, including:
- Oncology
- Cell and gene therapy
- Precision medicine
- Combination products
- Companion diagnostics
- Antibody and peptide conjugates
As therapeutic modalities become more interconnected, the traditional boundaries between drugs, biologics, devices, and diagnostics are rapidly disappearing. This increasing complexity creates new demands for integrated regulatory expertise.
Julie believes Global RWC is uniquely positioned to support these evolving programs by combining biotech and medtech capabilities under a single collaborative structure. “More integration means a stronger regulatory strategy,” she noted.
Innovation Happens at the Boundaries
One of the most compelling themes from the conversation was Julie’s emphasis on collaboration across “invisible work boundaries.”
She encouraged professionals to look beyond their immediate responsibilities and identify opportunities to improve communication, coordination, and process handoffs.
“Sometimes the most valuable opportunities aren’t in the core of what you’re doing,” Julie shared. “They’re at the edges.”
Whether through strategic partnerships, cross-functional collaboration, or smarter systems, Julie believes meaningful innovation often emerges where disciplines intersect.
And throughout it all, her focus remains firmly centered on people.
Helping patients, building strong teams, creating momentum, and making the path to innovation just a little easier for everyone involved. We couldn’t agree more.
About Life Sciences – In Focus
Life Sciences – In Focus Podcast by Visatatec, a fascinating conversation with global life sciences experts. The show has multiple hosts and topics. Follow Life Sciences – In Focus on Spotify for all the latest episodes, or subscribe to the show on YouTube and Apple podcasts. Life Sciences – In Focus is available on many other podcast platforms. To learn more about the podcast, please visit https://vistatec.com/life-sciences-division.
About Vistatec
We have been helping some of the world’s most iconic brands to optimize their global commercial potential since 1997. Vistatec is one of the world’s leading global content solutions providers. HQ in Dublin, Ireland, with offices in Mountain View, California, USA. To learn more about Vistatec, please visit https://www.vistatec.com